Valve-in-valve transcatheter aortic valve implantation: The issues behind crossing a bioprosthesis.
Aortic valve recrossing
Structural valve deterioration
TAVI
ViV TAVI
Journal
Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
received:
10
11
2023
revised:
19
12
2023
accepted:
20
12
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
30
12
2023
Statut:
aheadofprint
Résumé
Valve-in-valve transcatheter aortic valve implantation (ViV TAVI) is rapidly arising as a safe and effective alternative to redo-surgery in the treatment of bioprostheses deterioration. While scientific community is currently focusing its attention on the most common limitations related to this procedure, such as the risk of coronary obstruction and patient-prosthesis mismatch, data regarding the first step of a ViV TAVI, the crossing of a degenerated bioprosthesis, are still lacking. The aim of this review is to analyze the available information about bioprosthesis crossing, to show the inherent challenges encountered by interventional cardiologists during valve crossing and to describe the current strategies to perform a correct crossing.
Identifiants
pubmed: 38160130
pii: S1553-8389(23)00969-7
doi: 10.1016/j.carrev.2023.12.015
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Prof M Montorfano receive consultant fees from Abbott, Boston, Kardia and Medtronic. Prof A Chieffo received speaker/consultant fees from Abiomed, Boston Scientific, Medtronic, Menarini, Shockwave Medical. Dr. Ancona received consultant fees from Abbott and Abiomed. Other authors have no relationships relevant to the contents of this paper to disclose.